Introduction
============

Adrenocortical carcinoma (ACC) is a rare and highly aggressive malignancy with an annual incidence of 0.7-2.0 cases per million individuals. The initial manifestations of ACC are Cushing\'s syndrome and/or virilization presenting as an abdominal mass or the feeling of abdominal fullness. Acute pancreatitis has never been reported as an initial manifestation of ACC.

There are various causes of acute pancreatitis, including alcohol, choledocholithiasis, hypertriglyceridemia, pancreatic divisum, sphincter of Oddi dysfunction, and pancreatic tumors. Metastasis-induced acute pancreatitis (MIAP) is very rare and initially manifests as cancer. In cases of MIAP, the original cancer is usually in the lung, especially small cell lung cancer (SCLC), although renal cell carcinoma has also been reported.

We herein report the first case of a patient with ACC presenting as an initial manifestation of MIAP and reveal that endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) can be used to diagnose metastasis from ACC.

Case Report
===========

A 26-year-old woman visited our hospital with upper abdominal pain. Her medical history and family history were not remarkable. She worked as a bar hostess and so consumed alcohol habitually (\>100 g ethanol per day) and smoked.

Computed tomography (CT) showed a left adrenal tumor (110×77 mm in diameter), and imaging revealed acute pancreatitis (enlargement of the pancreatic parenchyma and stranding of the surrounding fat). Her serum amylase (1,084 U/L; normal range: 37.0-125 U/L), white blood cell count (9,940/mm^3^; normal range: 3,500-8,000/mm^3^), and C-reactive protein (18.0 mg/dL; normal range: 0.0-0.3 mg/dL) values were elevated. We diagnosed her with acute pancreatitis caused by alcohol and an incidental adrenal tumor. To diagnose the adrenal tumor, we conducted an endocrinologic examination. She had no typical symptoms of Cushing\'s syndrome, such as moon face or central obesity, pheochromocytoma, or virilization. There was no ^123^I metaiodobenzylguanidine uptake in the left adrenal tumor, and urine metanephrine and normetanephrine levels were within the normal range. Serum adrenocorticotropic hormone (ACTH) levels were low (\<1.0 pg/mL; normal range: 7.2-63.3 pg/mL), and dehydroepiandrosterone sulfate levels were high (2,493 μg/dL; normal range: 92-399 μg/mL). There was a lack of circadian rhythm of cortisol, and overnight low-dose dexamethasone (1 mg) suppression tests revealed a lack of cortisol suppression (before, 18.4 μg/dL; after 19.4, μg/dL).

Examinations revealed that she had non-ACTH-dependent Cushing\'s syndrome, not pheochromocytoma. Thereafter, we performed contrast-enhanced CT and positron emission tomography (PET) studies, which revealed a left adrenal tumor \[93×78×78.5 mm; maximum standardized uptake value (SUV~max~), 9.5\] with a solitary right lung metastasis (10×9.8 mm; SUV~max~, 3.9) ([Fig. 1](#g001){ref-type="fig"}).

![a, b) Contrast-enhanced computed tomography (CT) showing a large left adrenal tumor with heterogeneous enhancement (arrowhead) and a right pulmonary tumor (arrow). c, d) Positron 18F-fluorodeoxyglucose positron emission tomography with CT showing both tumors, with maximum standardized uptake values of 9.5 and 3.9.](1349-7235-58-2645-g001){#g001}

After her condition recovered with intravenous infusion, she underwent adrenalectomy with open surgery on hospital day 8. A pathologic examination revealed that the adrenal tumor was ACC according to the Weiss system. The tumor met 5 of the 9 criteria for ACC \[mitotic rate \>5/50 high-power fields, \<25% clear cells, diffuse architecture (\>1/3 of the tumor), necrosis, and sinusoidal invasion\], and the Ki67/MIB1 labeling index (Ki67/MIB1LI) of the tumor was 56% ([Fig. 2](#g002){ref-type="fig"}).

![Adrenocortical carcinoma of the left adrenal gland. a: Resected specimen. b: Clusters of tumor cells with eosinophilic cytoplasm and \<25% clear cells \[Hematoxylin and Eosin (H&E) staining, ×40\]. c: Sinusoidal invasion (H&E staining, ×200). d: Mitotic rate \>5/50 high-power fields (H&E staining, ×400).](1349-7235-58-2645-g002){#g002}

While preparing for pulmonary resection, she suffered a second upper abdominal attack on hospital day 22. Laboratory data showed that her serum amylase level and white blood cell count had increased (1,629 U/L and 11,260/mm^3^, respectively). CT showed acute pancreatitis and proximal main pancreatic duct (MPD) dilatation. Magnetic resonance cholangiopancreatography (MRCP) also revealed proximal MPD dilatation and diminishment of the distal MPD; however, neither imaging modality revealed a distal pancreatic mass ([Fig. 3](#g003){ref-type="fig"}). Therefore, we performed EUS to examine the pancreas on hospital day 27, which revealed a solitary pancreatic mass (8 mm in diameter) that obstructed the proximal pancreatic duct. Subsequently, we performed EUS-FNA with a 22-G needle (EZ shot 3 plus; Olympus, Tokyo, Japan) ([Fig. 4](#g004){ref-type="fig"}). Pathologic findings revealed a pancreatic mass that was a solitary pancreatic metastasis from ACC ([Fig. 5](#g005){ref-type="fig"}). We diagnosed the patient with acute pancreatitis attacks manifesting as MIAP. To prevent recurrent acute pancreatitis caused by pancreatic metastasis, we performed endoscopic pancreatic stenting (EPS) via the minor papilla through the MPD on hospital day 35. Thereafter, she did not experience acute pancreatitis, but the pancreatic metastasis increased in size. Synchronous multiple metastases from ACC required the initiation of mitotane-based chemotherapy (etoposide, doxorubicin, cisplatin, and mitotane) without resection of other organs. She underwent 12 cycles of mitotane-based chemotherapy, however, she ultimately died of the progression of ACC at 26.5 months after the first admission.

![CT and magnetic resonance imaging showing pancreatic dilatation in the pancreatic body and tail, which was not seen at admission. However, there was no obvious tumor in the pancreatic parenchyma (arrowhead).](1349-7235-58-2645-g003){#g003}

![A: Endoscopic ultrasonography revealing a pancreatic tumor (8 mm in diameter) in the pancreatic body (arrow). Arrowhead shows the pancreatic main duct. B: Needle penetrating the tumor.](1349-7235-58-2645-g004){#g004}

![A: Microscopically, the tumor cells had eosinophilic cytoplasm and mimicked the adrenocortical carcinoma. B: The Ki67/MIB1 labeling index of the specimen was 55%.](1349-7235-58-2645-g005){#g005}

Discussion
==========

This case is the first report of MIAP from ACC that was diagnosed by EUS-FNA according to a search of the PubMed database using the key words "metastasis-induced acute pancreatitis", "adrenocortical carcinoma" and "endoscopic ultrasonography-guided fine-needle aspiration". ACC is a rare and highly aggressive malignancy, with an annual incidence of 0.7-2.0 cases per million individuals. ACC can occur at any age but has a peak incidence at 40-50 years, and women are more often affected than men, accounting for 55-60% of all cases ([@B1]).

Complete surgical resection is the only potentially curative treatment for ACC ([@B2]). However, metastasis is common in patients with ACC, with approximately one-third of patients having synchronous metastasis at the diagnosis ([@B3]). The most common metastatic sites are lung, liver, and bone. After initial resection, locoregional recurrence becomes a challenge with pelvic, peritoneal, or retroperitoneal metastases ([@B4]). In this case, liver metastasis was found three months after adrenalectomy, and she ultimately died of multiorgan disfunction from liver and lung metastases and peritoneal dissemination.

Pancreatic metastasis is rare compared with liver and lung metastasis. Adsay et al. reported secondary tumors of the pancreas in 81 (1.6%) of 4,955 adult autopsy cases and 38 (3.9%) of 973 surgical cases ([@B5]). The lung (34 cases), gastrointestinal tract \[stomach (10), colon (5), esophagus (4), rectum (1)\], kidney (4), breast (3), and liver (2) were the most frequent sites of primary in the autopsy series, and most were non-Hodgkin\'s lymphomas (11) in the surgical series ([@B5]).

According to a large single-center experience of diagnosing pancreatic metastases with EUS-FNA, the primary tumor sites were the kidney (21 cases), lung (8), skin (6), colon (4), breast (3), small bowel (2), stomach (2), liver (1), ovary (1), and bladder (1) in 49 patients. In addition, EUS-FNA confirmed pancreatic metastases in 47/49 patients (95.9%) without complications ([@B6]). The adrenal gland was not mentioned as a secondary tumor of the pancreas.

Baur et al. reported a case of pancreatic metastasis from ACC. Their case was one of recurrent ACC with a solitary pancreatic metastasis that occurred six years after resection of the primary tumor ([@B7]).

The current case was MIAP. Two weeks before the second attack of acute pancreatitis, PET-CT showed no proximal pancreatic duct dilatation or pancreatic mass. We did not perform MRCP at the first attack of acute pancreatitis because we considered the etiology to have been alcohol, given the patient\'s history of alcohol intake. We might have been able to detect narrowing of the MPD or slight upstream dilatation had we performed MRCP after the first attack. At the second attack, CT and MRCP revealed proximal pancreatic duct dilatation but no solitary pancreatic mass. In contrast, EUS showed an obvious solitary pancreatic mass and EUS-FNA revealed pancreatic metastasis from ACC on pathological findings.

EUS is now regarded as the most sensitive imaging modality for the detection of pancreatic lesions. According to a systematic review, the overall sensitivities of EUS, CT, US, and MRI for the detection of pancreatic tumors were 94%, 74%, 67%, and 79%, respectively ([@B8]). For the detection of pancreatic tumor ≤20 mm, EUS had a higher sensitivity than contrast-enhanced CT (94.4% vs. 50.0%, n=36) ([@B9]). Furthermore, EUS-FNA is the best modality for obtaining a tissue diagnosis; it has a sensitivity of 85-86.8% and specificity of 95.8-98% for determining the etiology of a solid pancreatic mass ([@B10], [@B11]).

There are no standard treatment approaches for MIAP due to the rarity of this disease and its poor prognosis. However, several authors reported that MIAP in patients with SCLC was treated successfully with chemotherapy to achieve pancreatic metastasis shrinkage and loss without recurrent acute pancreatitis ([@B12], [@B13]). In the current case, ACC showed poor responsiveness to chemotherapy and radiotherapy; therefore, we inserted a pancreatic stent through the pancreatic metastasis from the minor papilla and decompressed the proximal pancreatic duct, similar to the EPS performed for MPD strictures in patients with chronic pancreatitis ([@B14]). On reviewing the literature, Oku et al. reported that EPS was previously performed for MIAP to prevent recurrent acute pancreatitis ([@B15]).

In the current case, we were unable to determine whether alcohol or pancreatic metastasis caused the first attack of pancreatitis. However, her proximal MPD was dilated slightly on CT performed after the first attack, and had had no episodes of acute pancreatitis despite being a heavy drinker. Therefore, we suspect that pancreatic metastasis caused the acute pancreatitis.

In conclusion, we should consider the possibility of pancreatic tumor when we encounter cases of acute pancreatitis with uncertain causes. EUS is a useful modality for detecting small pancreatic masses, and we emphasize the efficacy of EUS-FNA for the diagnosis of pancreatic metastasis.
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